BENEVOLENTAI DRUG PIPELINE
Affects 10-20% of children and up to 3% of adults.(1)
Mild to moderate AD affects approximately 70% of all patients.(2)
Global prevalence is rising.
89% of patients reported limited treatment effectiveness and/or harm with their current treatment options.(3)
"This is an exciting time for BenevolentAI and as we evaluate the safety and efficacy of this drug, we are hoping to see results that could significantly improve the quality of life for children and adults suffering from this disease."
(1) Atopic Dermatitis: Epidemiology Forecast to 2027 - GlobalData Report Store, 2021. [Accessed March 2021]
(2) Atopic Dermatitis: Epidemiology Forecast to 2027 - GlobalData Report Store, 2021. [Accessed March 2021]
(3) McCleary et al. More Than Skin Deep “Voice of the Patient”. Report, 2020. Available from: https://www.aafa.org/media/2628/more-than-skin-deep-voice-of-the-patient-report.pdf. [Accessed April 2021].